Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 1/20 | 0.47 |
| ▸ | PPARA | Q07869 | 1/20 | 0.47 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.46 |
| ▸ | KEAP1 | Q14145 | 7/20 | 0.44 |
| ▸ | NFE2L2 | Q16236 | 6/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | GRN | P28799 | 1/20 | 0.40 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.40 |
| ▸ | CTSS | P25774 | 1/20 | 0.40 |
| ▸ | CTSK | P43235 | 1/20 | 0.40 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.39 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.39 |
| ▸ | PRCP | P42785 | 1/20 | 0.39 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20521905 | 1.00 | PPARG (0.47) | PPARGPPARATRPA1KEAP1NFE2L2 | |
| SCHEMBL23205818 | 1.00 | PPARG (0.47) | PPARGPPARATRPA1KEAP1NFE2L2 | |
| SCHEMBL26230744 | 0.89 | TRPA1 (0.46) | PPARGPPARATRPA1S1PR3ALDH1A1 | |
| SCHEMBL26231308 | 0.89 | TRPA1 (0.46) | PPARGPPARATRPA1S1PR3ALDH1A1 | |
| SCHEMBL26647713 | 0.87 | CTSS (0.47) | KEAP1NFE2L2CYP2C9ALDH1A1MAPT | |
| SCHEMBL6443317 | 0.87 | PPARA (0.48) | PPARGPPARATRPA1S1PR3ALDH1A1 | |
| SCHEMBL15165758 | 0.87 | KEAP1 (0.51) | PPARGPPARAKEAP1NFE2L2MAPT | |
| SCHEMBL1573516 | 0.87 | KEAP1 (0.51) | PPARGPPARAKEAP1NFE2L2MAPT | |
| SCHEMBL5862225 | 0.87 | KEAP1 (0.51) | PPARGPPARAKEAP1NFE2L2MAPT | |
| SCHEMBL6513379 | 0.86 | KEAP1 (0.42) | PPARGPPARAKEAP1NFE2L2CTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250074900-A1 | ISOINDOLINONE INHIBITORS OF THE MDM2-P53 INTERACTION AND PROCESS FOR MAKING THEM | ASTEX THERAPEUTICS LIMITED (GB) | 2025-03-06 | — | — | US | disclosed |
| US-20240293364-A1 | BIOMARKERS FOR CANCER THERAPY USING MDM2 ANTAGONISTS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2024-09-05 | — | — | US | disclosed |
| US-12077526-B2 | Isoindolinone inhibitors of the MDM2-P53 interaction and process for making them | ASTEX THERAPEUTICS LIMITED (GB) | 2024-09-03 | — | — | US | disclosed |
| EP-4301875-A1 | BIOMARKERS FOR CANCER THERAPY USING MDM2 ANTAGONISTS | Otsuka Pharmaceutical Co., Ltd. (JP) | 2024-01-10 | — | — | EP | disclosed |
| US-20230338337-A1 | BIOMARKERS FOR CANCER THERAPY USING MDM2 ANTAGONISTS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2023-10-26 | — | — | US | disclosed |
| US-20230338337-A1 | BIOMARKERS FOR CANCER THERAPY USING MDM2 ANTAGONISTS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2023-10-26 | — | — | US | disclosed |
| US-20230313313-A1 | BIOMARKERS FOR CANCER THERAPY USING MDM2 ANTAGONISTS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2023-10-05 | — | — | US | disclosed |
| US-20230313313-A1 | BIOMARKERS FOR CANCER THERAPY USING MDM2 ANTAGONISTS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2023-10-05 | — | — | US | disclosed |
| US-20230278989-A1 | ISOINDOLINONE INHIBITORS OF THE MDM2-P53 INTERACTION AND PROCESS FOR MAKING THEM | ASTEX THERAPEUTICS LIMITED (GB) | 2023-09-07 | — | — | US | disclosed |
| US-20230278989-A1 | ISOINDOLINONE INHIBITORS OF THE MDM2-P53 INTERACTION AND PROCESS FOR MAKING THEM | ASTEX THERAPEUTICS LIMITED (GB) | 2023-09-07 | — | — | US | disclosed |
| WO-2022043930-A2 | BIOMARKERS FOR CANCER THERAPY USING MDM2 ANTAGONISTS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2022-03-03 | — | — | WO | disclosed |
| WO-2022043930-A2 | BIOMARKERS FOR CANCER THERAPY USING MDM2 ANTAGONISTS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2022-03-03 | — | — | WO | disclosed |
| WO-2021130682-A2 | BIOMARKERS FOR CANCER THERAPY USING MDM2 ANTAGONISTS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2021-07-01 | — | — | WO | disclosed |
| WO-2021130682-A2 | BIOMARKERS FOR CANCER THERAPY USING MDM2 ANTAGONISTS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2021-07-01 | — | — | WO | disclosed |
| US-20210101887-A1 | ISOINDOLINONE INHIBITORS OF THE MDM2-P53 INTERACTION AND PROCESS FOR MAKING THEM | ASTEX THERAPEUTICS LIMITED (GB) | 2021-04-08 | — | — | US | disclosed |
| US-20210101887-A1 | ISOINDOLINONE INHIBITORS OF THE MDM2-P53 INTERACTION AND PROCESS FOR MAKING THEM | ASTEX THERAPEUTICS LIMITED (GB) | 2021-04-08 | — | — | US | disclosed |
| EP-3601272-A1 | ISOINDOLINONE INHIBITORS OF THE MDM2-P53 INTERACTION AND PROCESS FOR MAKING THEM | Astex Therapeutics Limited (GB) | 2020-02-05 | — | — | EP | disclosed |
| WO-2018178691-A1 | ISOINDOLINONE INHIBITORS OF THE MDM2-P53 INTERACTION AND PROCESS FOR MAKING THEM | ASTEX THERAPEUTICS LIMITED (GB) | 2018-10-04 | — | — | WO | disclosed |
| US-7041667-B1 | CCR5 modulators | PFIZER, INC. (US) | 2006-05-09 | — | — | US | disclosed |
| EP-1013276-A1 | Aminoazacycloalkanes as CCR5 modulators | PFIZER INC. (US) | 2000-06-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240293364-A1 | BIOMARKERS FOR CANCER THERAPY USING MDM2 ANTAGONISTS | MSH2, MRE11, RAD50 | PPARG 3045/4885PPARA 2999/4885TRPA1 4382/4885 |
| US-12077526-B2 | Isoindolinone inhibitors of the MDM2-P53 interaction and process for making them | MDM2, TP53, TP53BP1 | PPARG 1840/4885PPARA 1452/4885TRPA1 4093/4885 |
| US-20230313313-A1 | BIOMARKERS FOR CANCER THERAPY USING MDM2 ANTAGONISTS | SKP2, MDM2, TP53 | PPARG 4083/4885PPARA 3664/4885TRPA1 4743/4885 |
| US-20230338337-A1 | BIOMARKERS FOR CANCER THERAPY USING MDM2 ANTAGONISTS | IRF2BP2, BST2, IRF3 | PPARG 3735/4885PPARA 3803/4885TRPA1 4027/4885 |
| US-20230278989-A1 | ISOINDOLINONE INHIBITORS OF THE MDM2-P53 INTERACTION AND PROCESS FOR MAKING THEM | MDM2, TP53, TP53BP1 | PPARG 1840/4885PPARA 1452/4885TRPA1 4093/4885 |
| US-20250074900-A1 | ISOINDOLINONE INHIBITORS OF THE MDM2-P53 INTERACTION AND PROCESS FOR MAKING THEM | MDM2, TP53, TP53BP1 | PPARG 1840/4885PPARA 1452/4885TRPA1 4093/4885 |
| US-20210101887-A1 | ISOINDOLINONE INHIBITORS OF THE MDM2-P53 INTERACTION AND PROCESS FOR MAKING THEM | MDM2, TP53, TP53BP1 | PPARG 1840/4885PPARA 1452/4885TRPA1 4093/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.